Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835323 | 1.00 | HTR2A (0.40) | HTR2ASLC6A4KCNH2GPR139RAPGEF4 | |
| SCHEMBL17790211 | 0.85 | ALDH1A1 (0.36) | HTR2ASLC6A4KCNH2SLC6A2ALDH1A1 | |
| SCHEMBL4150839 | 0.85 | TSHR (0.40) | HTR2ASLC6A4KCNH2GPR139RAPGEF4 | |
| SCHEMBL4827313 | 0.85 | ALDH1A1 (0.36) | HTR2ASLC6A4KCNH2SLC6A2ALDH1A1 | |
| SCHEMBL4832250 | 0.85 | TSHR (0.40) | HTR2ASLC6A4KCNH2GPR139RAPGEF4 | |
| SCHEMBL4827316 | 0.85 | ALDH1A1 (0.36) | HTR2ASLC6A4KCNH2SLC6A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5394551 | 0.83 | TSHR (0.38) | HTR2ASLC6A4KCNH2GPR139ALDH1A1 | |
| SCHEMBL4547915 | 0.79 | TRPM8 (0.38) | KCNH2GPR139RAPGEF4TRPM8SLC6A2 | |
| SCHEMBL20868259 | 0.77 | RAPGEF4 (0.39) | GPR139RAPGEF4TRPM8SLC6A2EPAS1 | |
| SCHEMBL30512228 | 0.77 | RAPGEF4 (0.39) | GPR139RAPGEF4TRPM8SLC6A2EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442692-B2 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-28 | — | — | US | disclosed |
| EP-1707564-B1 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
| EP-1707564-A2 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | HTR2A 86/4885SLC6A4 27/4885KCNH2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.